FDA Grants Accelerated Approval to Zongertinib in HER2 NSCLC
Zongertinib gains FDA approval for advanced NSCLC with HER2 mutations, showcasing promising efficacy and safety in clinical trials.
Related Articles
Improving Mental Health for Stem Cell Transplant Caregivers
A digital app significantly enhances the quality of life for caregivers of stem cell transplant patients, reducing stress and improving coping abilities.
Improving ACCESS to Stem Cell Transplant for All Patients
A groundbreaking study enhances stem cell transplant access for diverse patients, improving outcomes with mismatched donors and innovative techniques.
Final Analysis of TALAPRO-2 in mCRPC Confirms Significant Benefit
New research reveals that combining talazoparib with enzalutamide significantly enhances survival rates in metastatic prostate cancer patients, regardless of genetic factors.
Neoadjuvant Pembrolizumab and Enfortumab Vedotin Improve Outcomes in MIBC
New trial results reveal that pembrolizumab and enfortumab vedotin significantly enhance survival rates for muscle-invasive bladder cancer patients ineligible for cisplatin.
FDA Accepts NDA for Vepdegestrant in ER+/HER2- Metastatic Breast Cancer
The FDA accepts a new drug application for vepdegestrant, a promising oral PROTAC developed by Arvinas and Pfizer, signaling potential breakthroughs in treatment.
The Targeted Pulse: Your Weekly Oncology Wrap-Up
Discover the latest breakthroughs in oncology, including FDA approvals and innovative therapies reshaping cancer treatment landscapes.
Immunoglobulin Replacement Therapy Not Shown to Lower Serious Infection Risk in CLL
Despite its increased use, immunoglobulin replacement therapy does not lower the risk of serious infection in patients with chronic lymphocytic leukemia.
Bexmarilimab Responses in High-Risk MDS Continue to Improve
Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted precision medicine strategies.
FDA Expands Approval for Tocilizumab Biosimilar to Treat CRS
FDA expands tocilizumab-anoh’s indication for treating cytokine release syndrome, enhancing treatment options for patients undergoing CAR T-cell therapy.